CellaVision AB (publ) (CEVI.ST)
SEK 207.5
(2.72%)
SEK 207.5
(2.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 130.3 Million SEK | 10.12% |
| 2022 | 118.33 Million SEK | -5.59% |
| 2021 | 125.33 Million SEK | 40.07% |
| 2020 | 89.48 Million SEK | -9.77% |
| 2019 | 99.17 Million SEK | 11.82% |
| 2018 | 88.68 Million SEK | 27.2% |
| 2017 | 69.72 Million SEK | 16.59% |
| 2016 | 59.8 Million SEK | 13.21% |
| 2015 | 52.82 Million SEK | 67.88% |
| 2014 | 31.46 Million SEK | 66.2% |
| 2013 | 18.93 Million SEK | 193.47% |
| 2012 | 6.45 Million SEK | -55.91% |
| 2011 | 14.63 Million SEK | -61.84% |
| 2010 | 38.34 Million SEK | 38.34% |
| 2009 | 27.72 Million SEK | 10.64% |
| 2008 | 25.05 Million SEK | 854.44% |
| 2007 | 2.62 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 38.54 Million SEK | 27.98% |
| 2024 Q1 | 30.12 Million SEK | -40.27% |
| 2024 Q3 | 31.11 Million SEK | -19.29% |
| 2023 Q4 | 50.43 Million SEK | 94.25% |
| 2023 Q2 | 34.7 Million SEK | 80.68% |
| 2023 FY | 130.3 Million SEK | 10.12% |
| 2023 Q1 | 19.2 Million SEK | -40.52% |
| 2023 Q3 | 25.96 Million SEK | -25.2% |
| 2022 Q4 | 32.29 Million SEK | 211.06% |
| 2022 FY | 118.33 Million SEK | -5.59% |
| 2022 Q1 | 38.4 Million SEK | -3.4% |
| 2022 Q2 | 37.25 Million SEK | -3.0% |
| 2022 Q3 | 10.38 Million SEK | -72.13% |
| 2021 Q2 | 31 Million SEK | 8.81% |
| 2021 Q4 | 39.75 Million SEK | 52.35% |
| 2021 Q1 | 28.49 Million SEK | -0.4% |
| 2021 FY | 125.33 Million SEK | 40.07% |
| 2021 Q3 | 26.09 Million SEK | -15.82% |
| 2020 Q1 | 20.27 Million SEK | -16.85% |
| 2020 Q4 | 28.6 Million SEK | 114.29% |
| 2020 FY | 89.48 Million SEK | -9.77% |
| 2020 Q3 | 13.34 Million SEK | -51.02% |
| 2020 Q2 | 27.25 Million SEK | 34.4% |
| 2019 Q2 | 30.27 Million SEK | 10.76% |
| 2019 Q3 | 17.17 Million SEK | -43.29% |
| 2019 Q1 | 27.33 Million SEK | -7.48% |
| 2019 FY | 99.17 Million SEK | 11.82% |
| 2019 Q4 | 24.38 Million SEK | 42.01% |
| 2018 Q1 | 19.02 Million SEK | 9.76% |
| 2018 FY | 88.68 Million SEK | 27.2% |
| 2018 Q4 | 29.54 Million SEK | 75.88% |
| 2018 Q3 | 16.8 Million SEK | -27.96% |
| 2018 Q2 | 23.32 Million SEK | 22.61% |
| 2017 Q4 | 17.32 Million SEK | 124.66% |
| 2017 Q1 | 25.29 Million SEK | 41.89% |
| 2017 Q2 | 19.39 Million SEK | -23.32% |
| 2017 Q3 | 7.71 Million SEK | -60.23% |
| 2017 FY | 69.72 Million SEK | 16.59% |
| 2016 Q4 | 17.82 Million SEK | 17.56% |
| 2016 FY | 59.8 Million SEK | 13.21% |
| 2016 Q2 | 16.9 Million SEK | 70.53% |
| 2016 Q3 | 15.16 Million SEK | -10.31% |
| 2016 Q1 | 9.91 Million SEK | -34.85% |
| 2015 Q4 | 15.21 Million SEK | -37.67% |
| 2015 Q3 | 24.41 Million SEK | 380.08% |
| 2015 Q2 | 5.08 Million SEK | -37.3% |
| 2015 FY | 52.82 Million SEK | 67.88% |
| 2015 Q1 | 8.11 Million SEK | -30.38% |
| 2014 Q1 | 5.89 Million SEK | -54.06% |
| 2014 FY | 31.46 Million SEK | 66.2% |
| 2014 Q4 | 11.64 Million SEK | 141.28% |
| 2014 Q3 | 4.82 Million SEK | -46.91% |
| 2014 Q2 | 9.09 Million SEK | 54.29% |
| 2013 Q2 | -314 Thousand SEK | 79.04% |
| 2013 Q3 | 7.91 Million SEK | 2620.06% |
| 2013 Q4 | 12.83 Million SEK | 62.15% |
| 2013 FY | 18.93 Million SEK | 193.47% |
| 2013 Q1 | -1.49 Million SEK | 53.1% |
| 2012 Q4 | -3.19 Million SEK | -182.07% |
| 2012 Q1 | 2.64 Million SEK | -64.04% |
| 2012 Q2 | 3.11 Million SEK | 17.67% |
| 2012 Q3 | 3.89 Million SEK | 25.14% |
| 2012 FY | 6.45 Million SEK | -55.91% |
| 2011 Q3 | 4.99 Million SEK | 127.69% |
| 2011 FY | 14.63 Million SEK | -61.84% |
| 2011 Q4 | 7.34 Million SEK | 47.25% |
| 2011 Q1 | 101 Thousand SEK | -99.73% |
| 2011 Q2 | 2.19 Million SEK | 2070.3% |
| 2010 Q2 | 8.12 Million SEK | 271.54% |
| 2010 Q3 | -2.14 Million SEK | -126.42% |
| 2010 Q1 | -4.73 Million SEK | -122.64% |
| 2010 FY | 38.34 Million SEK | 38.34% |
| 2010 Q4 | 37.1 Million SEK | 1828.32% |
| 2009 Q3 | 5.36 Million SEK | 485.26% |
| 2009 Q1 | 518 Thousand SEK | -97.28% |
| 2009 Q4 | 20.92 Million SEK | 290.32% |
| 2009 Q2 | 916 Thousand SEK | 76.83% |
| 2009 FY | 27.72 Million SEK | 10.64% |
| 2008 FY | 25.05 Million SEK | 854.44% |
| 2008 Q2 | 1.42 Million SEK | 0.0% |
| 2008 Q3 | 3.39 Million SEK | 138.41% |
| 2008 Q4 | 19.04 Million SEK | 461.09% |
| 2007 FY | 2.62 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 267.408% |
| ADDvise Group AB (publ) | 103.5 Million SEK | -25.902% |
| ADDvise Group AB (publ) | 103.5 Million SEK | -25.902% |
| Arcoma AB | 2.56 Million SEK | -4982.254% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 194.166% |
| BICO Group AB (publ) | -835.7 Million SEK | 115.593% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | -421.716% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 263.311% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 546.467% |
| C-Rad AB (publ) | 35.52 Million SEK | -266.768% |
| Duearity AB (publ) | -26.19 Million SEK | 597.553% |
| Dignitana AB (publ) | -17.36 Million SEK | 850.498% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 237.457% |
| Getinge AB (publ) | 2.41 Billion SEK | 94.597% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 291.695% |
| Iconovo AB (publ) | -45.89 Million SEK | 383.936% |
| Integrum AB (publ) | 4.03 Million SEK | -3131.487% |
| Luxbright AB (publ) | -25.37 Million SEK | 613.53% |
| Mentice AB (publ) | -2.81 Million SEK | 4725.808% |
| OssDsign AB (publ) | -130.49 Million SEK | 199.859% |
| Paxman AB (publ) | 8.33 Million SEK | -1464.334% |
| Promimic AB (publ) | -9.22 Million SEK | 1513.023% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 181.466% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 334.432% |
| ScandiDos AB (publ) | -14.64 Million SEK | 989.663% |
| Sectra AB (publ) | 428.38 Million SEK | 69.582% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 318.595% |
| Senzime AB (publ) | -134.14 Million SEK | 197.138% |
| SpectraCure AB (publ) | -20.44 Million SEK | 737.488% |
| Stille AB | 26.64 Million SEK | -389.038% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 103.384% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | -41.918% |